Skip to main content

Geriatric Urogynecology & Reconstructive Urology

Geriatric urogynecology and reconstructive urology addresses the unique challenges of managing pelvic floor disorders (PFDs) — pelvic organ prolapse (POP), urinary incontinence (UI), fecal incontinence (FI), and genitourinary syndrome of menopause (GSM) — in older women, a population expected to grow by 46% by 2050.[1] The central principle is that chronological age alone should not determine treatment eligibility; rather, individualized decisions should be guided by frailty status, comorbidity burden, functional capacity, patient goals, and life expectancy.[2][3]

Epidemiology and Impact​

UI prevalence reaches approximately 75% in women aged ≥75 years, yet at least half do not report it to their physicians.[4] POP prevalence similarly increases with age, and roughly 13% of women undergo prolapse surgery in their lifetime.[5] These conditions are major drivers of nursing-home admission (6% of admissions for elderly women) and carry enormous economic burden ($19.5 billion annually in the U.S.).[4] Mixed incontinence becomes increasingly common with age, and the distinction between stress and urgency UI is often less clear in older women.[4][6]

Preoperative Geriatric Assessment and Frailty​

Assess frailty and functional reserve before elective pelvic-floor surgery in older adults. Frailty — a multidimensional syndrome of decreased physiologic reserve — is present in 30–50% of older patients presenting for major surgery and independently predicts postoperative morbidity, mortality, loss of independence, and prolonged hospitalization.[7][8]

For the urogynecologic setting:[3][9][7]

  • Timed Up and Go (TUG) — ≥15 seconds indicates compromised mobility.
  • Clinical Frailty Scale (CFS-9) — rapid, picture-based; AUC 0.86–0.91 vs. Fried Frailty Index in pelvic-floor patients.[9]
  • Mini-Cog — screens for cognitive impairment (critical for medication management and self-catheterization capacity).
  • Robinson Frailty Index — used in the ASPIRe trial; scores ≥2 indicate prefrail / frail status.[10]
  • Life-Space Assessment — evaluates mobility and community engagement.

A urogynecology review proposes TUG, Life-Space Assessment and Mini-Cog as a practical battery; this is not a universally mandated three-test requirement for every patient aged ≥65.[3]

ASPIRe frailty substudy​

ASPIRe (2026, n = 146 women ≥65 years undergoing prolapse surgery) found that prefrail / frail participants had few immediate complications, without a detected increase compared with nonfrail patients, but had a 2.1-fold higher hazard of treatment failure (aHR 2.1, 95% CI 1.2–3.6). Prefrail/frail participants living alone were more likely to require enhanced social support in the first 6 weeks (19% vs. 6%, P = 0.04).[10]

Comprehensive geriatric assessment should also address polypharmacy (particularly anticholinergic burden — see below), nutritional status, depression screening (PHQ-2), goals of care, and advance-care planning.[11][7]

Prehabilitation and ERAS​

Multimodal prehabilitation — combining exercise training, nutritional optimization, and anxiety reduction — may benefit frail older adults; the ASCRS colorectal-surgery guideline gives this Grade 1B, with individualized components and duration. Direct evidence for every pelvic-floor procedure is less certain.[12] The guideline cites 26 heterogeneous major-abdominal-surgery studies with fewer overall (OR 0.61), pulmonary (OR 0.41) and cardiac complications (OR 0.46), but age/frailty were not consistently reported; a separate 110-patient frail colorectal RCT found no advantage over postoperative rehabilitation.[12]

ERAS protocols specifically adapted for transvaginal pelvic-floor reconstruction in older women have been evaluated in a 2025 RCT (n = 100), demonstrating significantly shorter postoperative length of stay (65 vs. 74 hours, P < 0.01) along with reductions in postoperative pain scores and PONV.[13][14]

Nonsurgical Management of UI in Older Women​

Behavioral and conservative therapies remain first-line for all types of UI in older women:[15][4]

  • Pelvic floor physical therapy / PFMT — effective for stress, urgency, and mixed UI; ~50% satisfaction at 1 year for stress-predominant UI.[15]
  • Bladder training — timed voiding, urge-suppression techniques.
  • Fluid management — tailoring intake to thirst, renal/cardiac status and measured urine output, reducing excessive caffeine, and adjusting evening fluids for nocturia without dehydration.[15]
  • Weight loss — for obese women, combined with exercise.

A 2025 systematic review of conservative interventions in frail older adults (12 RCTs, n = 1,580) found an uncertain effect on objective UI measures (six pooled RCTs; g = −0.39, 95% CI −0.832 to 0.060), with very low certainty and substantial heterogeneity. No adverse events were reported, but incomplete reporting cannot establish absence of risk.[16]

Pessaries can be useful when fitting is comfortable and reliable follow-up is feasible, including caregiver support when cognition or dexterity is limited.[17][18] The 2026 UK multidisciplinary guideline recommends an initial review at 4–6 weeks and, by expert consensus, no longer than six months between clinic-managed reviews; this is not a requirement to replace every pessary every 4–6 weeks. Inability to maintain follow-up or self-manage makes ongoing use unsafe.[45]

Pharmacotherapy: The Anticholinergic Burden Problem​

This is one of the most critical geriatric-specific considerations in urogynecology. Observational studies associate cumulative OAB anticholinergic exposure with dementia, but confounding and reverse causation limit causal interpretation:[19][20][21]

  • A large French nested case-control study (n = 28,860) found an adjusted OR of 1.48 (95% CI 1.22–1.80) for dementia with >365 defined daily doses of OAB anticholinergics. Oxybutynin and solifenacin carried the highest risk, while trospium (with limited blood-brain-barrier penetration) had no detected association in that study; this does not establish zero long-term risk.[19]
  • A 2025 meta-analysis (n = 3.66 million) reported an association with 20% higher dementia risk with anticholinergics vs. no therapy (RR 1.2) and a 28% increased risk vs. mirabegron (RR 1.28).[21]
  • A 2026 systematic review found pooled HR of 1.24 (95% CI 1.19–1.30) for cognitive decline / dementia, with additional observational associations for cardiovascular events (OR 1.13) and mortality (OR 1.26). Short RCTs (mean 19.5 days) detected no cognitive difference; that duration cannot resolve long-term dementia risk, and the review identified bias concerns.[22]

Society recommendations​

  • The SUFU White Paper states that chronic use (>3 months) of OAB anticholinergics is "likely associated with an increased risk of new-onset dementia" and recommends earlier progression to advanced therapies (botulinum toxin, neuromodulation).[20]
  • The 2023 AGS Beers Criteria lists bladder antimuscarinics as strongly anticholinergic, notes the strongest cognitive-harm evidence for oxybutynin, and urges caution with all agents. Consider cognition, falls and the total medication burden.[23]
  • AUA/SUFU 2024 recommends discussing dementia/cognitive-impairment risk and selecting therapy through shared decision-making, rather than using age alone to decide eligibility.[43]

Preferred pharmacologic alternatives​

β3-adrenergic agonists (mirabegron, vibegron) have broadly comparable symptom efficacy to anticholinergics for OAB symptoms but do not contribute to anticholinergic burden.[24][25][26] In a network meta-analysis of older adults (≥65 years), mirabegron had:[24]

  • Similar efficacy across all endpoints (micturition frequency, incontinence episodes, urgency).
  • Dry-mouth incidence similar to placebo (vs. 3.8–7.9× higher with antimuscarinics).
  • No increased odds of adverse-event-related discontinuation (OR 0.99 vs. placebo).

Mirabegron can raise blood pressure; monitor BP and avoid use in severe uncontrolled hypertension. This is not a uniform class effect: the vibegron ambulatory-BP study did not show a clinically significant increase. Both require attention to retention risk and agent-specific interactions.[27]

Minimally Invasive Therapies in Older Women​

AUA/SUFU 2024 permits these treatments through shared decision-making without mandatory trials of every earlier category. Consider access, procedural burden, dexterity, cognition and caregiver support.[43]

  • OnabotulinumtoxinA (Botox) — FDA-approved for adult OAB with inadequate response to or intolerance of an anticholinergic; the label does not require failure of a β3 agonist; effective in older women but carries risk of urinary retention requiring self-catheterization (which may be impractical with limited dexterity or cognitive impairment).[28][18]
  • Percutaneous tibial nerve stimulation (PTNS) — office-based, minimally invasive; 30-minute weekly sessions for 12 weeks then maintenance. Effective for urgency UI with very few side effects, making it well suited for elderly patients who cannot tolerate medications or are poor surgical candidates. Indirect network rankings do not prove that PTNS is best for every older patient.[29][30]
  • Sacral neuromodulation (SNM) — more invasive (implanted device); success rates of 29–76% for ≥50% improvement in leakage. Importantly, poor response to PTNS does not predict failure of SNM — a negative PTNS trial should not preclude an SNM trial. SNM is also FDA-approved for fecal incontinence.[31][32]

Surgical Management of POP in Geriatric Patients​

Patient selection​

FactorConsideration
Frailty statusPrefrail / frail patients have 2.1× higher treatment failure; plan for enhanced social support postoperatively
Cardiovascular diseaseIndependent risk factor for perioperative complications (blood transfusion, pulmonary edema, CHF); CAD and PVD are strongest predictors
Cognitive statusAffects ability to manage pessaries, perform CIC, adhere to postoperative restrictions; screen with Mini-Cog
Sexual activity goalsDetermines whether obliterative vs. reconstructive approach is appropriate
ASA classHigher ASA associated with colpocleisis selection; however, ASA / CCI alone do not reliably predict complications
Life expectancyInfluences whether durable repair (sacrocolpopexy) vs. simpler procedure is warranted

Surgical approaches by geriatric context​

Colpocleisis (obliterative surgery) is an option for patients who do not wish to retain vaginal penetrative sexual function, particularly when comorbidity makes a shorter procedure attractive. Discuss its irreversible vaginal closure and future examination limitations; comorbidity alone does not determine the choice.[17] Key outcomes:[33][35]

  • In women ≥75 years, colpocleisis patients are older with more comorbidities than those undergoing reconstructive repair, yet have no detected difference in complication rates and shorter LOS in an observational cohort (1.2 vs. 1.7 days, P = 0.03).[33]
  • A 2026 single-center series (n = 58, mean age 75.6 years) reported 94.8% anatomic success, 77.5% subjective success, and only a 6.8% regret rate at mean 2.9-year follow-up. No patients regretted loss of sexual function. Significant improvements were seen in all pelvic-symptom domains (PFDI-20 decreased from 78.1 to 16.6, P < 0.001).[35]

Vaginal native-tissue repair remains the most common reconstructive approach in women ≥75 years (43.7% of prolapse repairs in this age group), followed by colpocleisis (42.3%) and sacrocolpopexy (14%).[33]

Sacrocolpopexy offers the most durable anatomic outcomes, but involves longer operative time and greater physiologic stress. In ASPIRe, frail patients undergoing any approach (including sacrocolpopexy) had few immediate complications, but higher long-term treatment failure.[10]

Complications in the elderly​

A retrospective study of 267 women ≥75 years found a 25.8% perioperative complication rate, with the most common being blood transfusion / significant blood loss, pulmonary edema, and postoperative CHF. Independent risk factors were operative time, coronary artery disease, and peripheral vascular disease — not age or comorbidity indices alone.[34] A large single-center study of women ≥80 years (n = 720) found that intraoperative complications occurred in only 1.5% and postoperative complications were mainly minor (Clavien-Dindo I–II), with no procedure-related deaths.[2]

Septuagenarians and older patients have an approximately 3-fold higher risk of mild early postoperative complications (OR 2.86, 95% CI 1.76–4.66) but no detected increase in major complications in the cited retrospective study.[36]

Genitourinary Syndrome of Menopause (GSM)​

GSM is a chronic, progressive condition affecting 45–77% of postmenopausal women, with symptoms worsening with age and time since menopause.[37] See GSM for the full framework. Geriatric-specific points:

  • Vaginal estrogen reduces recurrent UTIs — a major source of morbidity, hospitalization, and antibiotic use in elderly women.[39][40]
  • Vaginal estrogen diminishes urinary urgency (unlike oral systemic estrogen, which increased incontinence in the WHI trial).[39]
  • Low-dose vaginal estrogen formulations can improve GSM symptoms; comparative evidence does not establish identical efficacy for every product or symptom. Choose according to symptoms, preferences, handling and cost.[37][38]
  • FDA approved revised labeling for an initial six menopausal hormone products, including a vaginal product, in February 2026 after initiating changes in November 2025. Check the specific current label; neither the older universal-boxed-warning claim nor a claim that all products are now warning-free is accurate.[44]
  • Progestogen is not needed for endometrial protection with low-dose vaginal estrogen based on 1-year safety data; postmenopausal bleeding nonetheless requires evaluation.[39]
  • Vaginal estrogen is underused in documented GSM — 9.0% of 1,838,732 Medicare beneficiaries with GSM-related diagnoses filled a prescription in the cited cohort; this is not an estimate for every eligible postmenopausal woman.[37]

Other options include moisturizers/lubricants and, for appropriate indications, vaginal prasterone or oral ospemifene. These drugs are not interchangeable with vaginal estrogen for rUTI prevention or OAB; breast-cancer history and agent-specific warnings matter. See the linked GSM page.[41][42]

Fecal Incontinence in Older Women​

FI prevalence increases markedly with age and is a leading cause of nursing-home placement. Management principles in the elderly:[32]

  • Conservative first — dietary fiber, stool-bulking agents, loperamide, biofeedback.
  • Sacral neuromodulation — first-line surgical treatment regardless of sphincter integrity; success rates ~63% at 6–12 months, declining to ~54% long-term.[32]
  • Sphincteroplasty — considered when EAUS demonstrates a discrete sphincter defect, though outcomes deteriorate over time.
  • PTNS — insufficient evidence for routine use in FI; an RCT showed no significant difference vs. sham (38% vs. 31% response).[32]

For diagnostic workup, see Anorectal Function & Defecography.

Summary of Geriatric-Specific Principles​

DomainKey Geriatric Principle
AssessmentScreen for frailty (TUG, CFS, Mini-Cog) rather than relying on chronological age; comprehensive geriatric assessment before elective surgery
MedicationsDiscuss observational dementia risk; often favor β3 agonists while checking their precautions and total anticholinergic burden
Conservative RxPessaries require comfortable fit and reliable examination/follow-up; tailor PFMT and behavioral care to functional ability
Vaginal estrogenUnderutilized; reduces UTIs, urgency, and vaginal symptoms; low-dose treatment usually does not need progestogen; evaluate bleeding and individual contraindications
Surgical selectionOffer colpocleisis when loss of vaginal penetration is acceptable; observed shorter stays do not prove equivalent risk
Perioperative careERAS protocols reduce LOS, pain, and PONV; prehabilitation improves functional capacity and reduces complications
Postoperative planningFrail patients need enhanced social support for 6 weeks; higher long-term treatment failure with frailty
Minimally invasive therapiesPTNS is well suited for elderly (office-based, minimal side effects); Botox effective but self-catheterization may be impractical
Goals of careShared decision-making incorporating life expectancy, functional goals, sexual-activity preferences, and caregiver capacity

See Also​

References​

1. Rashid TF, Alkassis M, Griebling TL, et al. "Management Approaches for Advanced Pelvic Organ Prolapse in the Geriatric Population." Clin Geriatr Med. 2025;41(2):275-288. doi:10.1016/j.cger.2025.01.008

2. Kołodyńska A, Kamińska A, Strużyk A, et al. "Geripausal Women — a New Challenge for Urogynecology in Upcoming Years." J Clin Med. 2026;15(2):530. doi:10.3390/jcm15020530

3. Shaw JS, Erekson E, Richter HE. "The Impact of Frailty in Older Women Undergoing Pelvic Floor Reconstructive Surgery." Menopause. 2020;28(3):332-336. doi:10.1097/GME.0000000000001681

4. Qaseem A, Dallas P, Forciea MA, et al. "Nonsurgical Management of Urinary Incontinence in Women: A Clinical Practice Guideline From the American College of Physicians." Ann Intern Med. 2014;161(6):429-440. doi:10.7326/M13-2410

5. Raju R, Linder BJ. "Evaluation and Management of Pelvic Organ Prolapse." Mayo Clin Proc. 2021;96(12):3122-3129. doi:10.1016/j.mayocp.2021.09.005

6. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. "Urinary Incontinence in Women: A Review." JAMA. 2017;318(16):1592-1604. doi:10.1001/jama.2017.12137

7. Kim DH, Rockwood K. "Frailty in Older Adults." N Engl J Med. 2024;391(6):538-548. doi:10.1056/NEJMra2301292

8. McIsaac DI, MacDonald DB, Aucoin SD. "Frailty for Perioperative Clinicians: A Narrative Review." Anesth Analg. 2020;130(6):1450-1460. doi:10.1213/ANE.0000000000004602

9. Amin KA, Lee W, Moskowitz D, et al. "A Rapid Method to Preoperatively Assess Frailty for Older Patients With Pelvic Floor Conditions." J Urol. 2020;203(6):1172-1177. doi:10.1097/JU.0000000000000739

10. Erekson E, Menefee SA, Whitworth R, et al. "Outcomes by Frailty and Mobility in Older Patients Undergoing Major Urogynecologic Surgery: A Planned Supplementary Study of the ASPIRe Trial." Am J Obstet Gynecol. 2026;234(3):689-729. doi:10.1016/j.ajog.2025.11.002

11. Zietlow KE, Wong S, Heflin MT, et al. "Geriatric Preoperative Optimization: A Review." Am J Med. 2022;135(1):39-48. doi:10.1016/j.amjmed.2021.07.028

12. Saur NM, Davis BR, Montroni I, et al. "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Perioperative Evaluation and Management of Frailty Among Older Adults Undergoing Colorectal Surgery." Dis Colon Rectum. 2022;65(4):473-488. doi:10.1097/DCR.0000000000002410

13. Huang X, Deng S, Lei X, et al. "Effect of Enhanced Recovery After Surgery on Older Patients Undergoing Transvaginal Pelvic Floor Reconstruction Surgery: A Randomised Controlled Trial." BMC Med. 2025;23(1):43. doi:10.1186/s12916-025-03880-y

14. Xiao Y, Hong S, Wan Y, et al. "Exploration of Enhanced Recovery After Surgery in Female Pelvic Floor Reconstruction: A Retrospective Study." Front Med. 2025;12:1659074. doi:10.3389/fmed.2025.1659074

15. ACOG Practice Bulletin No. 155. "Urinary Incontinence in Women." Obstet Gynecol. 2015;126(5):e66-e81. doi:10.1097/AOG.0000000000001148

16. O'Callaghan M, Robinson K, Whiston A, Senter M, Clifford AM. "The Effect of Conservative Non-Pharmacological Interventions on the Management of Urinary Incontinence in Older Adults Living With Frailty: Systematic Review and Meta-Analysis." PLoS One. 2025;20(5):e0322742. doi:10.1371/journal.pone.0322742

17. ACOG Practice Bulletin No. 214. "Pelvic Organ Prolapse." Obstet Gynecol. 2019;134(5):e126-e142. doi:10.1097/AOG.0000000000003519

18. Goode PS, Burgio KL, Richter HE, Markland AD. "Incontinence in Older Women." JAMA. 2010;303(21):2172-2181. doi:10.1001/jama.2010.749

19. Malcher MF, Droupy S, Berr C, et al. "Dementia Associated With Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database." J Urol. 2022;208(4):863-871. doi:10.1097/JU.0000000000002804

20. Zillioux J, Welk B, Suskind AM, Gormley EA, Goldman HB. "SUFU White Paper on Overactive Bladder Anticholinergic Medications and Dementia Risk." Neurourol Urodyn. 2022;41(8):1928-1933. doi:10.1002/nau.25037

21. Kotochinsky M, Mora L, Carrazzoni Godoi D, et al. "Risk of Dementia in Patients Treated With Anticholinergics for Overactive Bladder Syndrome: A Systematic Review and Meta-Analysis." Neurol Sci. 2025. doi:10.1007/s10072-025-08546-4

22. Maguire T, Marr C, Barry H, Abdel-Fattah M, McGuinness B. "Antimuscarinic Medication Used for the Treatment of Overactive Bladder in Women and the Risk of Cognitive Decline, Cardiovascular Disease and Mortality: A Systematic Review." Age Ageing. 2026;55(2):afag027. doi:10.1093/ageing/afag027

23. American Geriatrics Society Beers Criteria Update Expert Panel. "American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults." J Am Geriatr Soc. 2023;71:2052–2081. doi:10.1111/jgs.18372

24. Lozano-Ortega G, Walker DR, Johnston K, et al. "Comparative Safety and Efficacy of Treatments for Overactive Bladder Among Older Adults: A Network Meta-Analysis." Drugs Aging. 2020;37(11):801-816. doi:10.1007/s40266-020-00792-9

25. Kelleher C, Hakimi Z, Zur R, et al. "Efficacy and Tolerability of Mirabegron Compared With Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-Analysis." Eur Urol. 2018;74(3):324-333. doi:10.1016/j.eururo.2018.03.020

26. Wagg A, Nitti VW, Kelleher C, et al. "Oral Pharmacotherapy for Overactive Bladder in Older Patients: Mirabegron as a Potential Alternative to Antimuscarinics." Curr Med Res Opin. 2016;32(4):621-638. doi:10.1185/03007995.2016.1149806

27. Astellas and Sumitomo Pharma. Mirabegron and vibegron US prescribing information. Myrbetriq; Gemtesa.

28. AbbVie. BOTOX (onabotulinumtoxinA): US Prescribing Information. Adult OAB indication and urinary-retention precautions. Label.

29. Tutolo M, Ammirati E, Heesakkers J, et al. "Efficacy and Safety of Sacral and Percutaneous Tibial Neuromodulation in Non-Neurogenic Lower Urinary Tract Dysfunction and Chronic Pelvic Pain: A Systematic Review of the Literature." Eur Urol. 2018;73(3):406-418. doi:10.1016/j.eururo.2017.11.002

30. Yu TY, Yu CY, Escorpizo R, et al. "Comparison of Nonimplantable Electrical Stimulation in Women With Urinary Incontinence: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials." Sci Rep. 2024;14(1):26957. doi:10.1038/s41598-024-78358-7

31. Kapriniotis K, Jenks J, Toia B, et al. "Does Response to Percutaneous Tibial Nerve Stimulation Predict Similar Outcome to Sacral Nerve Stimulation?" Neurourol Urodyn. 2022;41(5):1172-1176. doi:10.1002/nau.24944

32. ACOG Practice Bulletin No. 210. "Fecal Incontinence." Obstet Gynecol. 2019;133(4):e260-e273. doi:10.1097/AOG.0000000000003187

33. Drain A, Escobar C, Pape D. "Prolapse Repair in the Elderly Patient: Contemporary Trends and 30-Day Perioperative Complications." Int Urogynecol J. 2020;31(10):2095-2100. doi:10.1007/s00192-020-04365-7

34. Stepp KJ, Barber MD, Yoo EH, et al. "Incidence of Perioperative Complications of Urogynecologic Surgery in Elderly Women." Am J Obstet Gynecol. 2005;192(5):1630-1636. doi:10.1016/j.ajog.2004.11.026

35. Yildiz Ç, Özdemir AZ, Barutçu B, et al. "Colpocleisis as an Obliterative Surgery for Pelvic Organ Prolapse: A Single-Center Experience." Medicine (Baltimore). 2026;105(4):e46411. doi:10.1097/MD.0000000000046411

36. Joukhadar R, Wöckel A, Herr D, et al. "Challenges of Longevity: Safety of Vaginal and Laparoscopic Urogynecological Procedures in Septuagenarians and Older Patients." Biomed Res Int. 2016;2016:5184595. doi:10.1155/2016/5184595

37. Gallo K, Zhang CA, Burton C, Kamdar N, Enemchukwu EA. "Vaginal Estrogen Utilization Among Medicare Beneficiaries With Genitourinary Syndrome of Menopause." JAMA Netw Open. 2025;8(12):e2549822. doi:10.1001/jamanetworkopen.2025.49822

38. Lethaby A, Ayeleke RO, Roberts H. "Local Oestrogen for Vaginal Atrophy in Postmenopausal Women." Cochrane Database Syst Rev. 2016;(8):CD001500. doi:10.1002/14651858.CD001500.pub3

39. Pinkerton JV. "Hormone Therapy for Postmenopausal Women." N Engl J Med. 2020;382(5):446-455. doi:10.1056/NEJMcp1714787

40. Hickey M, LaCroix AZ, Doust J, et al. "An Empowerment Model for Managing Menopause." Lancet. 2024;403(10430):947-957. doi:10.1016/S0140-6736(23)02799-X

41. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review." Ann Intern Med. 2024;177(10):1400-1414. doi:10.7326/ANNALS-24-00610

42. Chang JG, Lewis MN, Wertz MC. "Managing Menopausal Symptoms: Common Questions and Answers." Am Fam Physician. 2023;108(1):28-39.

43. American Urological Association/SUFU. Diagnosis and Treatment of Idiopathic Overactive Bladder. 2024. Official guideline.

44. U.S. Food and Drug Administration. "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products." February 12, 2026. Official release.

45. Brown C, Rantell A, Anders K, et al. "UK Clinical Guideline for Best Practice in the Use of Vaginal Pessaries for Pelvic Organ Prolapse." Neurourol Urodyn. 2026;45:1113–1151. doi:10.1002/nau.70306.